Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...
Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...
AbbVie’s dividend payout ratio is currently 227.78%. Insider Activity In other news, SVP Kevin K. Buckbee sold 1,800 shares of the company’s stock in a transaction on Monday, December 16th.
AbbVie has a 52 week low of $153.58 and a 52 week high of $207.32. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. Institutional Inflows and Outflows ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $224.00. The company’s shares closed yesterday ...
(RTTNews) - AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology ...
Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ...
AbbVie ABBV has outperformed the market over the past 5 years by 2.03% on an annualized basis producing an average annual return of 15.25%. Currently, AbbVie has a market capitalization of $299.79 ...
Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback